Accessing Pharma Assets: Having the Right People Helps

Out-licensing will never be a top priority for pharmaceutical firms. But where a biotech has insider knowledge of a particular program or group of programs within the larger firm, out-licensing is happening--sometimes without any clawbacks at all. This activity's helping create biotechs, and also helping them leap closer to market with nearly-approved drugs.